Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making
Si-Ye Chen, Yong Yang, Shu‐Nan Qi, Ying Wang, Chen Hu, Xia He, Liling Zhang, Gang Wu, Baolin Qu, Li-Ting Qian, Xiao-Rong Hou, Fu-Quan Zhang, Xue-Ying Qiao, Hua Wang, Gaofeng Li, Yu‐Jing Zhang, Yuan Zhu, Jian-Zhong Cao, Shengmin Lan, Jun-Xin Wu, Tao Wu, Su-Yu Zhu, Mei Shi, Liming Xu, Zhiyong Yuan, Joachim Yahalom, Richard Tsang, Yu-Qin Song, Jun Zhu, Hang Su, Ye‐Xiong Li
Abstract
Derived from our original nomogram study by using the risk variables from multivariable analyses in the derivation cohort of 1383 patients with extranodal NK/T-cell lymphoma, nasal-type (ENKTCL) who were mostly treated with anthracycline-based chemotherapy, we propose an easily used nomogram-revised risk index (NRI), validated it and compared with Ann Arbor staging, the International Prognostic Index (IPI), Korean Prognostic Index (KPI), and prognostic index of natural killer lymphoma (PINK) for overall survival (OS) prediction by examining calibration, discrimination, and decision curve analysis in a validation cohort of 1582 patients primarily treated with non-anthracycline-based chemotherapy. The calibration of the NRI showed satisfactory for predicting 3- and 5-year OS in the validation cohort. The Harrell's C-index and integrated Brier score (IBS) of the NRI for OS prediction demonstrated a better performance than that of the Ann Arbor staging system, IPI, KPI, and PINK. Decision curve analysis of the NRI also showed a superior outcome. The NRI is a promising tool for stratifying patients with ENKTCL into risk groups for designing clinical trials and for selecting appropriate individualized treatment.